Carisma Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focuses on developing immunotherapies for solid tumors, including CAR-M therapies CT-0508 and CT-0525. The company went public in February 2014 and employs 107 people.
CARM filed a patent for "chimeric antigen receptors including jak/stat binding domains and modified immune cells" on Thu, December 15, 2022.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
